New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 9, 2012
13:52 EDTPFE, BMYELIQUIS demonstrates superiority in prevention of recurrent VTE
Bristol-Myers Squibb Company (BMY) and Pfizer (PFE) announced the results of the Phase 3 AMPLIFY-EXT trial, which evaluated treatment with ELIQUIS (apixaban) over a one-year period compared to placebo for the prevention of recurrent venous thromboembolism, VTE, in 2,486 patients who had already completed 6 to 12 months of anticoagulation treatment for VTE, including deep vein thrombosis, DVT, or pulmonary embolism, PE. In the trial, extended treatment with ELIQUIS 2.5 mg and 5 mg twice daily, demonstrated superiority versus placebo in the reduction of the composite endpoint of symptomatic, recurrent VTE and death from any cause (11.6% in the placebo group, compared with 3.8% and 4.2% in the ELIQUIS 2.5 mg and 5 mg groups, respectively, P<0.001), the primary efficacy outcome of the trial.
News For BMY;PFE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | all recent news | >>
January 12, 2015
05:26 EDTBMYBristol-Myers up 5.6% after Opdivo Phase 3 study meets primary endpoint
Subscribe for More Information
05:06 EDTBMYBristol-Myers Opdivo Phase 3 study met primary endpoint
Bristol-Myers Squibb announced that an open-label, randomized Phase 3 study evaluating Opdivo versus docetaxel in previously treated patients with advanced, squamous cell non-small cell lung cancer, or NSCLC, was stopped early because an assessment conducted by the independent Data Monitoring Committee, or DMC, concluded that the study met its endpoint, demonstrating superior overall survival in patients receiving Opdivo compared to the control arm. The company will share these data – which for the first time indicate a survival advantage with an anti-PD1 immune checkpoint inhibitor in lung cancer – with health authorities. CheckMate -017 investigators are being informed of the decision to stop the comparative portion of the trial. Bristol-Myers Squibb is working to ensure that eligible patients will be informed of the opportunity to continue or start treatment with Opdivo in an open-label extension as part of the company’s commitment to providing patient access to Opdivo, and characterizing long-term survival. The company will complete a full evaluation of the final CheckMate -017 data and work with investigators on the future presentation and publication of the results.
<< 1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use